Cancer Discov. 2017 Aug;7(8):OF5. doi: 10.1158/2159-8290.CD-NB2017-090. Epub 2017 Jun 9.
Findings from the global phase III ALEX trial unequivocally show that alectinib is superior to crizotinib as first-line therapy for ALK+ non-small cell lung cancer. Alectinib more than doubled progression-free survival, significantly reduced the incidence of brain and CNS metastases, and should be considered the new standard of care.
来自全球 III 期 ALEX 试验的结果明确表明，阿来替尼作为 ALK+非小细胞肺癌的一线治疗药物优于克唑替尼。阿来替尼使无进展生存期延长了一倍以上，显著降低了脑和中枢神经系统转移的发生率，应被视为新的治疗标准。
